Coordinating Center for Beta Cell Biology Consortium

描述（由申请人提供）：作为对RFA-DK-09-504的回应，我们提出了一项β细胞生物学联盟（BCBC）协调中心未来活动的计划。该联盟最初于2001年9月启动，然后于2005年更新，为学习如何再生或替换被1型或2型糖尿病破坏或损坏的胰腺β细胞所需的研究带来了以团队为导向的方法。协调中心通过以下方式在联盟中发挥着至关重要的作用：1）组织研究者会议和务虚会，2）维护BCBC网站和试剂数据库，3）监督BCBC核心设施，4）提供先进的生物/信息学应用程序，5）管理特殊资助计划，6）提供各种类型的行政支持，以及7）促进与其他NIH赞助的中心和联盟的互动。在BCBC的下一个周期中，协调中心将1）继续执行许多正在进行的操作，2）适应科学重点和新参与者的变化，3）改进网站，以促进团队科学和未发表知识和试剂的共享。 公共卫生相关性：1型和2型糖尿病导致显著的发病率和死亡率，因此具有不利的经济影响。这两种疾病的特征在于分泌胰岛素的胰腺β细胞的破坏或功能障碍。该应用程序将协调科学家团队之间的活动，以开发新的基于细胞的替代疗法，有望实现比目前更好的血糖控制。

DESCRIPTION (provided by applicant): In response to RFA-DK-09-504 we present a plan for future activities of the Coordinating Center for the Beta Cell Biology Consortium (BCBC). This consortium, which was initially launched in September 2001 then renewed in 2005, brings a team-oriented approach to studies necessary to learn how to regenerate or replace pancreatic beta cells that are either destroyed or damaged by Type 1 or Type 2 diabetes. The Coordinating Center plays a vital role in the consortium by 1) organizing investigator meetings and retreats, 2) maintaining the BCBC website and reagent databases, 3) overseeing BCBC core facilities, 4) providing advanced bio/informatics applications, 5) managing special funding programs, 6) providing various types of administrative support, and 7) facilitating interactions with other NIH-sponsored Centers and Consortia. During the next cycle of the BCBC the Coordinating Center will 1) continue to perform many ongoing operations, 2) adapt to changes in the scientific focus and new participants, and 3) improve the website in a way to facilitate team science and sharing of unpublished knowledge and reagents. PUBLIC HEALTH RELEVANCE: Type 1 and Type 2 diabetes cause significant morbidity and mortality and thus have an adverse economic impact. Both diseases are characterized by the destruction or dysfunction of insulin-secreting pancreatic beta cells. This application will coordinate activities among a team of scientists in order to develop new, cell-based replacement therapies that hold promise for achieving better glucose control than is currently possible.